Drug Delivery System for Aflibercept Delivery in metastatic Colorectal Cancer (mCRC)

Background: Metastatic colorectal cancer (mCRC) is a major health burden worldwide and a growing challenge in Asian countries. Treatment options include chemotherapy and vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab) or anti-epidermal growth factor receptor (EGFR) therapy. Aflibercept, a recombinant fusion protein, is approved for the treatment of mCRC in combination with FOLFIRI in patients with disease progression during or after an oxaliplatin-containing regimen based on its efficacy and tolerability profile in clinical trials. Hence, the amount, dosage and side effects of chemotherapy even though they are highly reduced are still considerable challenges. The purpose of this report is to provide insight into the future production of a drug delivery system that can be sustainable and targeted and has fewer side effects. To achieve these goals, a DDS system was designed using an electrospinning method and nanoparticles filled with aflibercept. This system can be injected into any suspective mass. Anti-VEGFs are used as inhibitors and controllers of any suspicious changes in the digestive system. Also, by using the injection of this system into the rectum and prevent any possible side-effects.

Drug Delivery System for Aflibercept Delivery in metastatic Colorectal Cancer (mCRC) Keywords:

mCRC , Anti-VEGF , Aflibercept , IBB